-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, Vir’s Elebsiran And Tobevibart Meet Primary Endpoint In Phase 3 ECLIPSE 1 Hepatitis Delta Trial, 44% Achieve Undetectable Virus Plus ALT Normalization Versus 0% Delayed Treatment

Benzinga·11/09/2026 07:49:26
Listen to the news
  • Trial met all Phase 3 endpoints and regimen is well-tolerated with all patients completing 48 weeks of treatment
  • 100% of patients achieved virologic response at Week 24 with 79% of patients reaching undetectable virus (as defined by HDV RNA TND) at Week 48
  • Comprehensive regulatory filing package planned for U.S. FDA submission mid-2027